News and Updates

Discover stories from Breakthrough T1D about our research, advocacy, initiatives, and supporters.

The latest

Read the latest news from Breakthrough T1D.

Type 1 diabetes (T1D) occurs when the body’s immune system attacks the insulin-producing beta cells in the pancreas. But this doesn’t happen overnight—instead, it’s a gradual process of beta cell loss over time. As the immune system attacks and destroys more beta cells, insulin production decreases, leading to abnormal blood-sugar levels. Eventually, enough beta cells are […]

From March 15–18, more than 200 passionate, motivated Breakthrough T1D Advocates from all 50 states convened in Washington, D.C., for Breakthrough T1D 2026 Government Day. Government Day remains one of Breakthrough T1D’s most impactful ways to effect change. By bringing the lived type 1 diabetes (T1D) experience directly to policymakers, we are accelerating progress toward […]

Autoimmune diseases occur when a person’s immune system wrongly attacks the body’s healthy cells, tissues, and organs. This response can result in a range of conditions, depending on which parts of the body are affected. Autoimmune diseases are often called “invisible” because their symptoms are not always evident to the people around you. As a […]

Breakthrough T1D is back from Barcelona! The final two days of ATTD were jam-packed with more incredible updates across all areas of our mission. Breakthrough T1D staff chaired and participated in many sessions—including Breakthrough T1D Senior Vice President of Research, Esther Latres, Ph.D.; Vice President of Medical Affairs Anastasia Albanese O’Neill, Ph.D., APRN, CDCES; Senior […]

Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center. Below is everything you need to know from the first two days of this remarkable conference, including […]

Recent articles

Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]

Learn the basics about autoimmune disease, including prevalence in the U.S., possible causes, and why they are often called "invisible."

Breakthrough T1D Ride is more than cycling—it’s a movement to find cures for type 1 diabetes (T1D). No matter where you live, how you choose to ride, or how far you go, you’re surrounded by the T1D community—fellow riders, coaches, friends, and family—cheering you on at every milestone. A fully supported cycling experience, finish-line celebration, […]

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law, ensuring continued momentum toward better treatments, disease-modifying therapies, and cures. This legislation: These are huge wins for the T1D community […]

This article was written by Alecia Wesner (pictured above, right), a Participant Advisory Council (PAC) member, a Clinical Trial Education Volunteer, and long-time Breakthrough T1D supporter. Alecia’s story details her lived experiences with type 1 diabetes, participation in clinical trials, and her journey to joining the PAC. The views expressed by the author are her […]

Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]

Press releases

Read the latest press releases and statements from Breakthrough T1D.

View All

Get the Latest T1D Updates

Sign up for our monthly mission progress newsletter, The Pipeline, to stay up to date on everything you need to know about T1D, from research to advocacy, to clinical care - and everything in between.

  • This field is for validation purposes and should be left unchanged.